Director, New Product Value & Evidence Strategy

Biopharma Asia; New Jersey; In loco; USD 180.000 - 230.000; Tempo pieno

Descrizione del lavoro

Johnson & Johnson in Titusville, NJ seeks a Director, New Products Value and Evidence to lead US market access strategy, evidence generation, and payer engagement for pipeline products. You will shape strategic plans, coordinate cross-functional teams, and translate data into actionable insights for access decisions.

The role emphasizes leadership in evidence generation, regulatory alignment, and cross-stakeholder collaboration to sustain patient access and launch readiness within the evolving

Competenze

• Minimum 7+ years of relevant research experience.
• Expertise in healthcare industry, medical reimbursement, and economic evaluations.
• Strong leadership, collaboration, influencing, and communication skills.
• Ability to translate complex scientific information for diverse audiences.

Mansioni

• Lead US market access scientific strategy, evidence generation, and dissemination planning for pipeline products.
• Develop evidence to support differentiated value propositions for payer and access stakeholders.
• Ensure integration of NPVE priorities into plans and budgets.
• Manage studies, publications, and external communications with regulatory and commercial alignment.

Conoscenze

Leadership

Collaboration

Communication skills

Data analysis

Health economics

Real World Evidence

Payer insights

Formazione

Master's degree in Public Health / Health Policy / Epidemiology / Economics / Pharmacy

Doctorate or advanced degree preferred

Descrizione del lavoro

Johnson & Johnson in Titusville, NJ seeks a Director, New Products Value and Evidence to lead US market access strategy, evidence generation, and payer engagement for pipeline products. You will shape strategic plans, coordinate cross-functional teams, and translate data into actionable insights for access decisions.

The role emphasizes leadership in evidence generation, regulatory alignment, and cross-stakeholder collaboration to sustain patient access and launch readiness within the evolving